-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
Legend Biotech Corp. (LEGN) PT Raised to $77 at RBC Capital on Growth Potential
-
RBC Capital: 'Legend Biotech Corp. (LEGN) Still Undervalued'
-
RBC Capital on Legend Biotech Corp. (LEGN): 'We See A Compelling Valuation'
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
RBC Capital on Legend Biotech Corp. (LEGN): 'See An Attractive Entrypoint With Strong 2025 Growth Potential'
-
RBC Capital's Global Biotech Outlook Report: 'Top 2025 Ideas'
-
RBC Capital Reiterates Outperform Rating on Legend Biotech Corp. (LEGN)
-
Legend Biotech Corp. (LEGN) PT Raised to $86 at RBC Capital
-
Legend Biotech Announces Participation in Upcoming Investor Conference

